Adavosertib is a potent, selective ATP-competitive Wee1 inhibitor. It affects cell cycle and DNA damage response signaling by reducing CDK1 phosphorylation and abrogating the G2/M checkpoint, effectively inhibiting tumor cell proliferation and promoting apoptosis.
Adavosertib (AZD1775, MK-1775) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Adavosertib (AZD1775, MK-1775) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.